GenoMed to study blood pressure medication as universal viral antidote in mumps trial

By Lisa Kerner

Erie, Pa., April 19 - GenoMed, Inc. is planning a clinical trial for mumps using blood pressure medication that it believes may be a near-universal viral antidote, making vaccines and antiviral drugs unnecessary for all but the immunosuppressed population.

The company said this approach has been successful in treating West Nile virus encephalitis in humans for the past three summers and in birds for the past two summers.

"As with most viruses, disease in humans is caused by a 'cytokine storm,' not by the virus itself," chief executive officer and chief medical officer David Moskowitz said in a company news release.

"Our approach is to calm the 'cytokine storm' in the host and ignore the virus. Our goal is to turn the patient into an asymptomatic shedder, which is what happens normally."

GenoMed is a biotechnology company located in St. Louis.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.